Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Texas OKs experimental stem cell therapy rules

By R&D Editors | April 16, 2012

AUSTIN,
Texas (AP)—The Texas Medical Board on Friday approved new rules on
experimental stem cell therapies such as the one Gov. Rick Perry
underwent during back surgery last year, despite objections they don’t
do enough to protect patients and could led to an explosion of doctors
promoting unproven, expensive treatments.

The
rules require patients to give their consent, and a review board must
approve the procedure before doctors use stem cell treatments.

Supporters
say establishing formal rules will lead to more medical innovation by
opening doors for researchers in Texas. At the same time, board members
acknowledged they don’t know how many doctors are already performing
stem cell procedures, and several who voted in favor said the rules
provide the first layers of patient protection.

“We’re trying to be safe. It’s the wild, wild west right now,” said Dr. Scott Holliday, an anesthesiologist from Arlington.

The
Food and Drug Administration hasn’t approved using adult stem cells to
help people heal from surgery, but experimentation is common.

Some
scientists tout possible benefits of stem cell treatments, including
treatment for heart disease, diabetes and some cancers. Others argue
adult stem cell experimentation actually increases the risk of cancer
and can cause blood clots.

Perry,
who appointed the board, had stem cells taken from the fat in his own
body that were then grown in a lab. They were injected into his back and
his bloodstream during an operation to fuse part of his spine.

Celltex
Therapeutics Corp. of Houston, which is co-owned by Dr. Stanley Jones,
Perry’s friend who performed his operation, supported the rule approved
Friday.

Nathan
Kottcamp, a Celltex attorney, testified before the board and dismissed
predictions of an explosion of new stem cell labs promoting therapies.
Harvesting stem cells is a complex, expensive process that cost patients
up to $35,000, Kottcamp said.

Texas doctors using stem cell treatments are ethical and trying to help their patients, Kottcamp said.

“Critics seem to believe stem cell theories are little better than snake oil,” he lamented.

Jones
appeared before the board last year to tout stem cell therapies and
said thousands of Americans are going to other countries for treatments.
Texans should be able to get care in their home state, he said.

Supporters
of the rules said requiring treatments to be approved by review boards
is a critical step in favor of patient safety. Boards could be attached
to medical schools or hospitals, or be accredited, independent
for-profit review boards.

But
Leigh Turner, an associate professor at the University of Minnesota’s
Center for Bioethics & School of Public Health who has complained to
federal regulators about Celltex, warned that doctors will be able to
“shop around” for a for-profit review board that will give them a
favorable ruling.

“(Review board) is not necessarily high-quality review,” Turner said.

Texas
joins at least 10 other states, including California, Illinois and New
York, who have enacted rules governing stem cell research.

Board
member Dr. W. Roy Smythe, a surgeon from Temple, voted against the
rules, saying they do too little to protect patients or rein in doctors
touting unproven treatments.

“This
doesn’t put the cat in the bag. It allows more cats to proliferate,”
Smythe said. “I believe in giving patients hope. I’m against giving
false hope that empties patient’s bank accounts.”

Source: The Associated Press

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE